# Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders

> **NCT03601819** · PHASE1 · TERMINATED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 4 (actual)

## Conditions studied

- Lymphoma, T-Cell, Cutaneous
- Lymphoma, T-Cell, Peripheral
- Chronic Lymphocytic Leukemia
- Lymphoproliferative Disorders
- Waldenstrom Macroglobulinemia
- Lymphoplasmacytic Lymphoma
- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Pacritinib

## Key facts

- **NCT ID:** NCT03601819
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-15
- **Primary completion:** 2020-03-07
- **Final completion:** 2020-07-17
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2021-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03601819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03601819, "Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT03601819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*